Tetrathiomolybdate inhibits the reaction of cisplatin with human copper chaperone Atox1

Abstract

Cisplatin is a widely used anticancer drug in clinic, and ammonium tetrathiomolybdate ([(NH₄)₂MoS₄], TM) is a copper chelator used in clinic for the treatment of Wilson's disease. Recently, TM has been found to enhance the therapeutic effect of cisplatin; however, the origin of this effect is not clear. Here we found that TM can inhibit the reaction of cisplatin with Cu–Atox1 and prevent the protein unfolding and aggregation induced by cisplatin. Although Ag(I) binds to Atox1 in a way similar to Cu(I)–Atox1, TM does not prevent the reaction of Ag–Atox1 with cisplatin. This result indicates that the formation of a Mo-centered trimeric protein cluster in the TM–Cu–Atox1 system plays a role in the inhibitory effect. This work provides new insights into the mechanism by which TM enhances the cytotoxic efficacy of cisplatin and helps to circumvent cisplatin resistance of tumor cells.